Actions

Semaglutide and cardiovascular risk: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 July 2026

12 July 2026

  • curprev 18:2718:27, 12 July 2026Prab talk contribs 42,618 bytes −168 No edit summary
  • curprev 18:1218:12, 12 July 2026Prab talk contribs 42,786 bytes +42,786 Created page with "{{Short description|Semaglutide and cardiovascular risk, Wegovy heart-risk reduction, SELECT trial, Ozempic cardiovascular data, heart failure, kidney outcomes, and W8MD medical weight loss care}} {{DISPLAYTITLE:Semaglutide and cardiovascular risk}} __NOTOC__ {{Infobox drug | drug_name = Semaglutide and cardiovascular risk | image = 250px | caption = Semaglutide has evidence for reducing cardiovascular risk in selected patients wit..."